NGF and cancer: In this study, tanezumab met the primary endpoint by demonstrating greater improvement in daily average pain intensity at the index bone metastasis cancer pain site at week 8 compared to the placebo, highlighting the potential of anti-NGF therapies to reduce cancer pain [121].